First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer-Reference-Cited by-同舟云学术

First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer

Published:2001-01 Issue: Volume:37 Page:25-29
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Vogel C.,Cobleigh M.A.,Tripathy D.,Gutheil J.C.,Harris L.N.,Fehrenbacher L.,Slamon D.J.,Murphy M.,Novotny W.F.,Burchmore M.,Shak S.,Stewart S.J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor;Hudziak;Mol Cell Biol.,1989

2. Humanization of an anti-p185HER2 antibody for human cancer therapy;Carter;Proc Natl Acad Sci USA,1992

3. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts;Baselga;Cancer Res.,1998

4. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers;Pegram;Oncogene,1999

5. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs;Pietras;Oncogene,1998

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amine-terminated dendrimers: A novel method for diagnose, control and treatment of cancer;Cancer Epigenetics and Nanomedicine;2024

2. Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry);BMC Cancer;2022-06-02

3. Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer;OncoTargets and Therapy;2022-04

4. Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes;Biomedicines;2022-01-13

5. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer;Future Oncology;2021-12